Sonal Admane MD, MPH , Sarah Pasyar MS , Roland Bassett Jr. MS , Eduardo Bruera MD , David Hui MD, MSc
{"title":"生命末期谵妄的昼夜节律:两项随机对照试验的二次分析。","authors":"Sonal Admane MD, MPH , Sarah Pasyar MS , Roland Bassett Jr. MS , Eduardo Bruera MD , David Hui MD, MSc","doi":"10.1016/j.jpainsymman.2025.04.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Context</h3><div>The circadian pattern of restlessness in end-of-life delirium is understudied and poorly understood.</div></div><div><h3>Objective</h3><div>To examine the timing of breakthrough restlessness in patients with advanced cancer and end-of-life delirium admitted to an acute palliative care unit.</div></div><div><h3>Methods</h3><div>This is a secondary analysis of two randomized clinical trials that examined the effect of lorazepam (MAD trial) and neuroleptics (CHAD trial) in end-of-life delirium. In this study we examined the frequency of restlessness in 8-hour intervals (7 AM–3 PM, 3–11 PM, 11 PM–7 AM). Breakthrough restlessness was measured based on 1) rescue medications (neuroleptics or benzodiazepines) administered for breakthrough restlessness and 2) a Richmond Agitation-Sedation Scale (RASS) score ≥+1 (collected every 2–4 hours).</div></div><div><h3>Results</h3><div>This study included 128 patients (58 from MAD trial, 70 from CHAD trial); the mean age (SD) was 64 (12.5), and 57 (44.5%) were women. We found that 3–11 PM was significantly associated with greater rescue medication use in univariate analysis for both trials (MAD: Estimate: 0.35, 95% CI: 0.23–0.48, <em>P</em> < 0.001; CHAD: Estimate: 0.1, 95% CI: 0.07–0.12, <em>P</em> < 0.001). This association remained significant in multivariate analysis for CHAD (Estimate: 0.1, 95% CI: 0.07–0.12, <em>P</em> < 0.001). About 3–11 PM was also associated with greater episodes of RASS ≥+1 in MAD in univariate and multivariate analysis (Estimate:0.31, 95 % CI: 0.21–0.42, <em>P</em> < 0.001).</div></div><div><h3>Conclusion</h3><div>Delirious patients were more restless between 3 PM and 11 PM. This observation of “sundowning” may help clinicians to better anticipate this symptom, schedule monitoring and treatments, and educate patients and caregivers.</div></div>","PeriodicalId":16634,"journal":{"name":"Journal of pain and symptom management","volume":"70 2","pages":"Pages 131-139.e2"},"PeriodicalIF":3.5000,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Circadian Rhythm in End-Of-Life Delirium: A Secondary Analysis of Two Randomized Controlled Trials\",\"authors\":\"Sonal Admane MD, MPH , Sarah Pasyar MS , Roland Bassett Jr. MS , Eduardo Bruera MD , David Hui MD, MSc\",\"doi\":\"10.1016/j.jpainsymman.2025.04.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Context</h3><div>The circadian pattern of restlessness in end-of-life delirium is understudied and poorly understood.</div></div><div><h3>Objective</h3><div>To examine the timing of breakthrough restlessness in patients with advanced cancer and end-of-life delirium admitted to an acute palliative care unit.</div></div><div><h3>Methods</h3><div>This is a secondary analysis of two randomized clinical trials that examined the effect of lorazepam (MAD trial) and neuroleptics (CHAD trial) in end-of-life delirium. In this study we examined the frequency of restlessness in 8-hour intervals (7 AM–3 PM, 3–11 PM, 11 PM–7 AM). Breakthrough restlessness was measured based on 1) rescue medications (neuroleptics or benzodiazepines) administered for breakthrough restlessness and 2) a Richmond Agitation-Sedation Scale (RASS) score ≥+1 (collected every 2–4 hours).</div></div><div><h3>Results</h3><div>This study included 128 patients (58 from MAD trial, 70 from CHAD trial); the mean age (SD) was 64 (12.5), and 57 (44.5%) were women. We found that 3–11 PM was significantly associated with greater rescue medication use in univariate analysis for both trials (MAD: Estimate: 0.35, 95% CI: 0.23–0.48, <em>P</em> < 0.001; CHAD: Estimate: 0.1, 95% CI: 0.07–0.12, <em>P</em> < 0.001). This association remained significant in multivariate analysis for CHAD (Estimate: 0.1, 95% CI: 0.07–0.12, <em>P</em> < 0.001). About 3–11 PM was also associated with greater episodes of RASS ≥+1 in MAD in univariate and multivariate analysis (Estimate:0.31, 95 % CI: 0.21–0.42, <em>P</em> < 0.001).</div></div><div><h3>Conclusion</h3><div>Delirious patients were more restless between 3 PM and 11 PM. This observation of “sundowning” may help clinicians to better anticipate this symptom, schedule monitoring and treatments, and educate patients and caregivers.</div></div>\",\"PeriodicalId\":16634,\"journal\":{\"name\":\"Journal of pain and symptom management\",\"volume\":\"70 2\",\"pages\":\"Pages 131-139.e2\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-04-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of pain and symptom management\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0885392425005998\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pain and symptom management","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0885392425005998","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Circadian Rhythm in End-Of-Life Delirium: A Secondary Analysis of Two Randomized Controlled Trials
Context
The circadian pattern of restlessness in end-of-life delirium is understudied and poorly understood.
Objective
To examine the timing of breakthrough restlessness in patients with advanced cancer and end-of-life delirium admitted to an acute palliative care unit.
Methods
This is a secondary analysis of two randomized clinical trials that examined the effect of lorazepam (MAD trial) and neuroleptics (CHAD trial) in end-of-life delirium. In this study we examined the frequency of restlessness in 8-hour intervals (7 AM–3 PM, 3–11 PM, 11 PM–7 AM). Breakthrough restlessness was measured based on 1) rescue medications (neuroleptics or benzodiazepines) administered for breakthrough restlessness and 2) a Richmond Agitation-Sedation Scale (RASS) score ≥+1 (collected every 2–4 hours).
Results
This study included 128 patients (58 from MAD trial, 70 from CHAD trial); the mean age (SD) was 64 (12.5), and 57 (44.5%) were women. We found that 3–11 PM was significantly associated with greater rescue medication use in univariate analysis for both trials (MAD: Estimate: 0.35, 95% CI: 0.23–0.48, P < 0.001; CHAD: Estimate: 0.1, 95% CI: 0.07–0.12, P < 0.001). This association remained significant in multivariate analysis for CHAD (Estimate: 0.1, 95% CI: 0.07–0.12, P < 0.001). About 3–11 PM was also associated with greater episodes of RASS ≥+1 in MAD in univariate and multivariate analysis (Estimate:0.31, 95 % CI: 0.21–0.42, P < 0.001).
Conclusion
Delirious patients were more restless between 3 PM and 11 PM. This observation of “sundowning” may help clinicians to better anticipate this symptom, schedule monitoring and treatments, and educate patients and caregivers.
期刊介绍:
The Journal of Pain and Symptom Management is an internationally respected, peer-reviewed journal and serves an interdisciplinary audience of professionals by providing a forum for the publication of the latest clinical research and best practices related to the relief of illness burden among patients afflicted with serious or life-threatening illness.